American College of Cardiology 2023 Scientific Session & Expo together with World Congress of Cardiology (ACC.23/WCC)

New Orleans, Louisiana 04 March 2023 - 06 March 2023

No drawback to immediate complete revascularization in ACS

29 Mar 2023 by

Doing an immediate complete revascularization of coronary artery lesions is as safe as a staged complete revascularization approach in patients with acute coronary syndrome (ACS) and multivessel disease in the BIOVASC trial presented at ACC.23/WCC.

29 Mar 2023

Atorvastatin cardioprotective in lymphoma patients receiving anthracycline?

25 Mar 2023 by

Among patients with lymphoma receiving anthracycline-based chemotherapy, those who received atorvastatin for 12 months were significantly less likely to experience a cardiac dysfunction than those on placebo, according to the STOP-CA* trial presented at ACC.23/WCC.

25 Mar 2023

Less salt may be fatally counterproductive for people with heart failure

24 Mar 2023 by

Too little salt is not necessarily better for individuals with heart failure, with the results of a recent meta-analysis suggesting that sodium restriction in this population increases the risk of death.

24 Mar 2023

Low-carb, high-fat diet: Friend or foe?

24 Mar 2023 by

Revered by diet enthusiasts as a godsend in the weight loss arena, a low-carbohydrate, high-fat (LCHF*) diet appears to take the opposite pole from a cardiovascular (CV) standpoint, as researchers from Canada found high levels of bad cholesterol and apolipoprotein B (apoB) in individuals who adhered to this dietary pattern.

24 Mar 2023

Coordinated care improves use of CVD-preventive therapies in T2D

23 Mar 2023 by

A coordinated, multifaceted intervention of assessment, education, and feedback has resulted in an increase in the prescription of recommended, evidence-based therapies in adult patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (CVD), reveals a study presented at ACC 2023.

23 Mar 2023

Full anticoagulation dosing confers survival advantage in hospitalized COVID-19 patients

23 Mar 2023 by

A full, therapeutic dosing of anticoagulation flops for reducing the incidence of overall combined outcomes in noncritically ill patients hospitalized with COVID-19 as compared with prophylactic dosing, although there is a signal of benefit for mortality and disease progression with the therapeutic dosing, as shown in the FREEDOM COVID trial presented at ACC.23/WCC.

23 Mar 2023

Wrist-worn sensor predicts elevated hs-cTnI in ACS patients

22 Mar 2023 by

A novel transdermal infrared spectrophotometric sensor (transdermal-ISS) worn on the wrist may be used for quick and noninvasive prediction of elevated high-sensitivity cardiac Troponin-I (hs-cTnI) in real world settings, according to a study presented at ACC 2023.

22 Mar 2023

Bempedoic acid cuts CV events in statin-intolerant patients

21 Mar 2023 by

The use of bempedoic acid significantly reduced the risk of major adverse cardiovascular events (MACE) in patients with high cholesterol who are intolerant to statins in the phase III CLEAR* Outcomes trial presented at ACC.23/WCC.

21 Mar 2023

Add-on evolocumab improves plaque characteristics in statin-treated CAD patients

15 Mar 2023 by

In individuals with stable coronary artery disease (CAD), intensifying their lipid-lowering regimen with evolocumab, a PCSK9* inhibitor, led to improvements in coronary plaque characteristics on intravascular imaging, findings from the YELLOW III trial have shown.

15 Mar 2023

STELLAR trial offers hope for rare heart-lung disorder

13 Mar 2023 by

The phase III STELLAR trial lives up to its name, delivering stellar results and offering hope for patients with pulmonary arterial hypertension (PAH), a rare, progressive, life-threatening disorder affecting the heart and lungs, by adding sotatercept – a novel first-in-class activin signalling inhibitor – to background therapy.

13 Mar 2023